Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
52.15
+0.20 (0.38%)
At close: Dec 5, 2025, 4:00 PM EST
52.05
-0.10 (-0.19%)
After-hours: Dec 5, 2025, 7:55 PM EST
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.22B in the quarter ending September 30, 2025, with 2.77% growth. This brings the company's revenue in the last twelve months to $48.03B, up 1.26% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$48.03B
Revenue Growth
+1.26%
P/S Ratio
2.21
Revenue / Employee
$1,408,622
Employees
34,100
Market Cap
106.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BMY News
- 9 hours ago - Do These 3 Healthcare Stocks Need a Checkup? - The Motley Fool
- 1 day ago - Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Business Wire
- 1 day ago - Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 days ago - A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why. - Market Watch
- 2 days ago - Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Benzinga
- 2 days ago - Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Business Wire
- 2 days ago - Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know. - Barrons
- 2 days ago - Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease - Business Wire